Abstract
Stereotactic radiosurgery is well-established in the treatment of intracranial lesions, but its use in extracranial lesions is relatively new. Stereotactic radiation delivery technologies such as the CyberKnife ® (Accuray Incorporated, Sunnyvale, CA) are being used with increasing frequency to treat lesions outside the cranium, such as in the spine, thorax, and abdomen; lesions that were not previously amenable to radiosurgical treatment due to inherent motion. The critical role of imaging technologies in radiosurgery, both for planning treatments and assessing their effects, makes an understanding of developments in these technologies imperative for radiosurgery professionals. In this chapter, we review how positron emission tomography (PET) is combined with computed tomography (CT) to enhance disease staging, radiosurgery and radiotherapy planning, and follow-up.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002;53:89–112.
Wahl RL, Quint LE, Cieslak RD, et al. “Anatometabolic” tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993;34:1190–1197
Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369–1379.
Akhurst T, Chisin R. Hybrid PET/CT machines: optimized PET machines for the new millennium? J Nucl Med 2000;41:961–963.
Osman M, Cohade C, Leal J, et al. Direct comparison of FDG-PET and PET-CT imaging in staging and restaging patients with lung cancer. Journal of Nuclear Medicine 2002;43:151P.
Lardinois D, Weder W, Hany TF, et al. Staging of nonsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500–2507.
Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18FFDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004;45:1640–1646.
Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–1209.
Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama 2003;290:3199–3206.
Bradley JD, Perez CA, Dehdashti F, et al. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J Nucl Med 2004;45Suppl 1:96S–101S.
Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51–60.
Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167–177.
Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593–597.
Brianzoni E, Rossi G, Ancidei S, et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 2005;32:1392–1399.
Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853–863.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496–507.
Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005;49:95–108.
Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005;32:294–301.
Miller M, Nguyen N, Oliver D, et al. Added Value of 18F FDG-PET/CT in CyberKnife Stereotactic Radiosurgery. 5th Annual CyberKnife Users’ Meeting. Carlsbad, CA; 2006.
Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as of September 2006. J Nucl Med 2007;48Suppl 1:78S–88S.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Osman, M.M. et al. (2007). 18FDG-PET/CT for Treatment Planning and Follow-Up. In: Urschel, H.C., Kresl, J.J., Luketich, J.D., Papiez, L., Timmerman, R.D., Schulz, R.A. (eds) Treating Tumors that Move with Respiration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69886-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-69886-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69885-2
Online ISBN: 978-3-540-69886-9
eBook Packages: MedicineMedicine (R0)